Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
about
Psoriasis: classical and emerging comorbiditiesAnti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VIEconomic impact of biologic utilization patterns in patients with psoriatic arthritisTumor necrosis factor inhibitors - state of knowledge.Development of a transparent interactive decision interrogator to facilitate the decision-making process in health care.Effect of TNF-α inhibitors on transcriptional levels of pro-inflammatory interleukin-33 and Toll-like receptors-2 and -9 in psoriatic plaques.Evaluating the cost-effectiveness of biologic treatments for psoriatic arthritis: can we make better use of patient data registries?Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis.Administration costs of intravenous biologic drugs for rheumatoid arthritis.Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US.Pharmacoeconomic burden in the treatment of psoriatic arthritis: from systematic reviews to real clinical practice studies.Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis.Simultaneous multioutcome synthesis and mapping of treatment effects to a common scale.Altered bone biology in psoriatic arthritis.Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis.Diagnosing and treating psoriatic arthritis: an update.Psoriatic arthritis: recent progress in pathophysiology and drug development.Novel methods of measuring clinical outcomes from psoriasis and psoriatic arthritis clinical trials.How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis.Treatment of psoriasis with etanercept: the typical patient profile.The Clinical and Cost Effectiveness of Apremilast for Treating Active Psoriatic Arthritis: A Critique of the Evidence.New developments in our understanding of psoriatic arthritis and their impact on the diagnosis and clinical management of the disease.The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis.Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults.Estimating the returns to United Kingdom publicly funded musculoskeletal disease research in terms of net value of improved health outcomes.Pharmaceutical pricing in Japan: market evidence for rheumatoid arthritis treatment.Lengthening the time intervals between doses of biological agents in psoriatic arthritis patients: A single-center retrospective study.Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK.The Role of Biological and Small Molecule Therapy in the Management of Psoriatic Arthritis.
P2860
Q28088340-8DC66315-48DB-4A79-8F0E-9D975327E363Q28476636-CF42D749-79C3-485C-968E-B447F91E1944Q33840422-F1DCA997-7D1E-4E14-AB66-4F3B5C2670AAQ34974335-FE1ADF81-69E2-4A35-A502-3935A30FB748Q35180222-BCBCAD44-9095-42C7-930F-A04DD60AC40BQ36080973-E1A6E3EE-A531-4FC0-B1D1-9ADAA3C0EBACQ36404862-9CEC38D4-CBC3-4A68-9A68-E1FE15CEBBF8Q36479450-ED97C535-44EA-43A0-9199-657B50C8FBBDQ37301258-BEEC8300-CF42-4EB8-B8C8-542A99FF4D3CQ37453027-3DC7746B-5897-41D6-84D5-35A36C916C21Q37515034-9D0DA7ED-2379-44F9-9906-CA56781E8AF2Q37520856-2C466532-5A4C-474F-BDBD-649D97810802Q37709832-A765B272-A8F6-4F7A-A361-87F3E46AB21CQ38010645-66EF60C7-2ADE-4F40-9BE2-31F8C73B2F07Q38104769-8782BEAB-277D-4973-AECD-18596DD7915EQ38165235-CD5C2059-70C8-433E-9FC8-A567CB4A6482Q38194559-1F1C2EB2-C8B5-475C-A469-7015C27790DFQ38211315-F9D6A70D-5311-4621-AD1E-1C199790F6DAQ38687870-253A06E3-9B1B-4FCD-946A-905560652C1CQ38807058-316F8947-6B6A-4563-881C-0A7AABA5375CQ38858194-47E45828-71E9-4051-AA40-ECC00D6C2DEAQ39373505-EAC883EC-60C7-4463-B4F8-8DB440E1DFA3Q40676691-3280A0A3-0D4A-40C1-B224-EF6CF04C0178Q47093829-F75A0009-15DD-460B-9548-4D8EE18781F5Q47259944-54C97B0A-F9CD-49F3-961D-6FF3034F9D71Q47779251-D03F88C3-986B-43AC-84D3-432EB49A1696Q48004654-8B649A5F-0383-42E1-B852-8B328884BC30Q49850238-78EDE5EB-78EF-4393-8604-78A11C79D529Q55452701-C74E1C95-EA41-49EC-B445-2A94EB945817Q55631301-D7A9AD7E-520E-4524-9492-51D92CD990DF
P2860
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Etanercept, infliximab and ada ...... eview and economic evaluation.
@en
Etanercept, infliximab and ada ...... eview and economic evaluation.
@nl
type
label
Etanercept, infliximab and ada ...... eview and economic evaluation.
@en
Etanercept, infliximab and ada ...... eview and economic evaluation.
@nl
prefLabel
Etanercept, infliximab and ada ...... eview and economic evaluation.
@en
Etanercept, infliximab and ada ...... eview and economic evaluation.
@nl
P2093
P50
P356
P1476
Etanercept, infliximab and ada ...... review and economic evaluation
@en
P2093
D Spiegelhalter
M Sculpher
N Woolacott
P304
i-xxi, 1-329
P356
10.3310/HTA15100
P577
2011-02-01T00:00:00Z